Tag

Acquisitions

All articles tagged with #acquisitions

Rocket Lab's $8B Iridium Deal Signals a Bold Leap into Satellite Communications
business5 days ago

Rocket Lab's $8B Iridium Deal Signals a Bold Leap into Satellite Communications

Rocket Lab (RKLB) plans to acquire Iridium Communications (IRDM) for about $8 billion in a half-cash, half-stock deal, aiming to combine rocket-launch services with satellite-based mobile communications to compete with SpaceX’s Starlink and expand margins. The move could unlock significant long-term upside, but it comes with high risk: Rocket Lab is still unprofitable, the stock is volatile, and the acquisition’s closing and integration (expected in H1 2027) will drive the near-term trajectory. In Q1, Rocket Lab posted revenue growth of about 63.5% to $200.3 million, while reporting a per-share loss of $0.02; Iridium posted a net profit of roughly $114.4 million last year, and Rocket Lab’s own net loss was about $198.2 million, underscoring the substantial execution risk alongside potential synergy-driven gains.

From $40,000 and a Matrix-inspired name to a $23B Nasdaq tech empire
technology6 days ago

From $40,000 and a Matrix-inspired name to a $23B Nasdaq tech empire

An Italian startup that quietly built a sprawling tech conglomerate through roughly 50 acquisitions of struggling brands (including Evernote, AOL, Eventbrite and Vimeo) and heavy debt. After going public on Nasdaq, it raised about $1.68 billion and is valued at roughly $23 billion, driven by a large, highly paid team of “Spooners” who overhaul acquired products rather than selling them off. The approach, praised for reviving assets and criticized for layoffs and limited financial disclosure, sets up ongoing questions about the long-term performance of the holdings under Bending Spoons.

AI fears push Accenture stock to six-year low as growth outlook dims
business23 days ago

AI fears push Accenture stock to six-year low as growth outlook dims

Accenture’s shares hit their lowest since 2017 after it trimmed revenue guidance, reporting a 3% drop in new bookings to $19.3 billion for the quarter to May and forecasting full-year revenue growth of no more than 4%. The decline, driven by AI-driven disruption to traditional IT and outsourcing models, has slashed its market value to about $82 billion. CEO Julie Sweet pointed to AI-driven demand despite fears of automation reducing consulting needs, while the company counters with aggressive acquisitions—runZero, NetRise, Dragos, and UK AI start-up Faculty—to bolster AI capabilities and cybersecurity offerings.

Sega's Rovio bet falters as Angry Birds loses lift in a tougher mobile market
business26 days ago

Sega's Rovio bet falters as Angry Birds loses lift in a tougher mobile market

Sega Sammy’s 2023 $776 million purchase of Rovio to leverage Angry Birds and Beacon tech has produced a $200 million impairment, with profitability falling short of forecasts. Analysts attribute slower mobile growth, higher user-acquisition costs, and the lingering effects of Apple’s ATT, arguing that merely owning a mature IP isn’t enough in today’s market. Rovio is set to rebuild and pursue a broader transmedia strategy with new IP, while Sega reassesses how to monetize the brand and integrate Rovio’s tech, emphasizing cross-media, platform partnerships, and expanding beyond Angry Birds.

Sleep Number Files Chapter 11, Strikes Sale Pact With Sleep Country Canada
financial-and-business-news29 days ago

Sleep Number Files Chapter 11, Strikes Sale Pact With Sleep Country Canada

Sleep Number filed for Chapter 11 bankruptcy protection and announced a court-supervised sale process, naming Sleep Country Canada as the stalking-horse bidder in a potential North American bedding merger. The deal remains subject to higher bids, court approval, and customary closing conditions, with Sleep Number continuing normal operations and projecting up to $260 million in debtor-in-possession financing to support the process. The company is also reviewing its retail footprint, including seeking to reject leases for 44 non-operational locations, while indicating potential international expansion if the sale closes. Sleep Country Canada would gain Sleep Number’s smart-bed technology and wellness platform as part of the transaction.

Lilly expands infectious-disease portfolio with three-broker vaccine acquisitions
business1 month ago

Lilly expands infectious-disease portfolio with three-broker vaccine acquisitions

Eli Lilly is buying Curevo, LimmaTech Biologics, and Vaccine Company for up to $3.8 billion in upfront and milestone payments to broaden its infectious-disease pipeline. Curevo brings a shingles vaccine candidate, LimmaTech adds a Staphylococcus aureus vaccine program, and Vaccine Company offers vaccines targeting flaviviruses and an EBV-focused program, signaling Lilly’s shift toward preventative vaccines and a strategy to build a diversified vaccine portfolio alongside its strong oncology and metabolic franchises.

Lilly bets on prevention with triple acquisitions to boost infectious-disease portfolio
business1 month ago

Lilly bets on prevention with triple acquisitions to boost infectious-disease portfolio

Lilly will acquire Curevo, LimmaTech Biologics, and Vaccine Company to broaden its infectious-disease portfolio, spanning a shingles vaccine candidate, a bacterial-pathogen vaccine platform, and an EBV-focused virus-like particle vaccine, for up to about $3.83 billion in cash and milestone payments, subject to closing conditions.

Lilly bets $4B on infectious-disease push with three acquisitions
business1 month ago

Lilly bets $4B on infectious-disease push with three acquisitions

Eli Lilly said it will buy Curevo, LimmaTech Biologics and The Vaccine Company for almost $4 billion in cash to expand infectious-disease R&D, sending its shares higher in premarket trading. Curevo develops a shingles vaccine, LimmaTech targets resistant bacterial pathogens including STIs, and The Vaccine Company advances in vivo nanoparticle delivery technologies for drugs, genes, and diagnostics. The move comes as Lilly relies on Zepbound and Mounjaro for strong revenue and introduces Foundayo to compete with Novo Nordisk in obesity treatments.

Antitrust Lawsuit Accuses Lucky Strike of Bowling Monopoly
business2 months ago

Antitrust Lawsuit Accuses Lucky Strike of Bowling Monopoly

A Washington federal class-action accuses Lucky Strike Entertainment (formerly Bowlero) of building an illegal bowling monopoly through aggressive acquisitions, commanding about 35% of U.S. bowling revenue and 350+ centers, driving up prices and degrading quality; the suit seeks to unwind acquisitions and damages, while Lucky Strike says the claims are meritless and that it has expanded opportunities for the sport.

Lilly lifts 2026 outlook after strong Q1 2026 results and Foundayo FDA approval
business2 months ago

Lilly lifts 2026 outlook after strong Q1 2026 results and Foundayo FDA approval

Lilly posted a 56% YoY surge in Q1 2026 revenue to $19.8B, with GAAP EPS of $8.26 and non-GAAP EPS of $8.55, driven by volume growth despite lower realized prices; raised full-year revenue guidance to $82–$85B and non-GAAP EPS to $35.50–$37.00; highlighted regulatory progress including FDA approval of Foundayo (orforglipron) for obesity, plus pipeline advances across multiple programs; announced four acquisitions (Orna Therapeutics, Centessa, Kelonia, Ajax Therapeutics); and plans an Investment Community Meeting for December 7, 2026.

Xbox Unveils Four-Point Blueprint for Its Next Era
business2 months ago

Xbox Unveils Four-Point Blueprint for Its Next Era

Xbox leaders Asha Sharma and Matt Booty laid out a four-priority blueprint: hardware (Gen9 stabilization and Project Helix), content (expand first- and third-party portfolios and creator-centric franchises), experience (revamp discovery, customization, social features and developer-friendly tools), and services (fortify Game Pass with sustainable economics, aim for durable growth, push cloud play on TVs and affordable devices, and pursue deliberate M&A). They also noted a reevaluation of exclusivity, windowing, and AI, emphasizing transparency while acknowledging execution will take time.